NO301577B1 - Fremgangsmåte for fremstilling av en stabil vaksineblanding og fremgangsmåte for stabilisering av interleukin i en vaksineblanding - Google Patents

Fremgangsmåte for fremstilling av en stabil vaksineblanding og fremgangsmåte for stabilisering av interleukin i en vaksineblanding Download PDF

Info

Publication number
NO301577B1
NO301577B1 NO920161A NO920161A NO301577B1 NO 301577 B1 NO301577 B1 NO 301577B1 NO 920161 A NO920161 A NO 920161A NO 920161 A NO920161 A NO 920161A NO 301577 B1 NO301577 B1 NO 301577B1
Authority
NO
Norway
Prior art keywords
interleukin
antigen
bacterial
rhil
alum
Prior art date
Application number
NO920161A
Other languages
English (en)
Norwegian (no)
Other versions
NO920161D0 (no
NO920161L (no
Inventor
Subramonia Pillai
Garvin Bixler
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of NO920161D0 publication Critical patent/NO920161D0/no
Publication of NO920161L publication Critical patent/NO920161L/no
Publication of NO301577B1 publication Critical patent/NO301577B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO920161A 1989-07-14 1992-01-13 Fremgangsmåte for fremstilling av en stabil vaksineblanding og fremgangsmåte for stabilisering av interleukin i en vaksineblanding NO301577B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37974289A 1989-07-14 1989-07-14
PCT/US1990/003982 WO1991001143A1 (en) 1989-07-14 1990-07-16 Stable vaccine compositions containing interleukins

Publications (3)

Publication Number Publication Date
NO920161D0 NO920161D0 (no) 1992-01-13
NO920161L NO920161L (no) 1992-03-05
NO301577B1 true NO301577B1 (no) 1997-11-17

Family

ID=23498494

Family Applications (1)

Application Number Title Priority Date Filing Date
NO920161A NO301577B1 (no) 1989-07-14 1992-01-13 Fremgangsmåte for fremstilling av en stabil vaksineblanding og fremgangsmåte for stabilisering av interleukin i en vaksineblanding

Country Status (12)

Country Link
EP (1) EP0482076B1 (da)
JP (2) JP3485184B2 (da)
KR (1) KR0177179B1 (da)
AT (1) ATE121629T1 (da)
AU (1) AU648509B2 (da)
CA (1) CA2063587C (da)
DE (1) DE69018990T2 (da)
DK (1) DK0482076T3 (da)
ES (1) ES2075900T3 (da)
FI (1) FI104233B1 (da)
NO (1) NO301577B1 (da)
WO (1) WO1991001143A1 (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6642390A (en) * 1989-10-27 1991-05-31 Arch Development Corporation Methods and compositions for promoting immunopotentiation
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
GR1000881B (el) * 1990-08-06 1993-03-16 Praxis Biolog Inc Σταθερες συνθεσεις εμβολιου που περιεχουν ιντερλευκινες.
ZA919907B (en) * 1990-12-19 1992-08-26 Schering Corp Use of il-4 to enhance immune response to immunogens in vaccines
JPH07500813A (ja) * 1991-05-13 1995-01-26 リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア リポソーム多糖体ワクチン
DE4126983A1 (de) 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
EP0655927B1 (en) * 1992-08-10 1997-04-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Interleukin-4 stimulated t lymphocyte cell death
ZA936095B (en) * 1992-08-21 1994-03-14 Univ Melbourne Cytokine applications.
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
AU3541495A (en) * 1994-09-01 1996-03-22 Wisconsin Alumni Research Foundation Therapeutic remodeling in aids
US6509313B1 (en) * 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
DE69735856T2 (de) * 1996-05-31 2006-11-16 National University Of Ireland Maynooth, Maynooth Il-12 als adjuvanz für bordetella pertussis impfstoffe
TW586934B (en) * 1997-05-19 2004-05-11 Sumitomo Pharma Immunopotentiating composition
US6270758B1 (en) 1998-10-08 2001-08-07 Duke University Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects
US6027731A (en) * 1998-11-17 2000-02-22 Wisconsin Alumni Research Foundation Pertussis toxin induced lymphocytosis
IT1302534B1 (it) 1998-12-21 2000-09-05 Fidia Advanced Biopolymers Srl Composizioni iniettabili, biocompatibili e biodegradabili comprendentialmeno un derivato dell'acido ialuronico, cellule condrogeniche, per
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
AU1813701A (en) 1999-12-03 2001-06-12 Celltech Chiroscience Limited Interleukin-1 muteins useful as vaccine adjuvants
US8663634B2 (en) 2005-07-11 2014-03-04 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
WO2007039584A1 (en) * 2005-09-30 2007-04-12 Lipoxen Technologies Limited Multivalent liposomal vaccine compositions comprising polysaccharide antigens and a protein adjuvant
CA2655080A1 (en) 2006-06-14 2007-12-21 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
JP2010520874A (ja) * 2007-03-09 2010-06-17 メルク・シャープ・エンド・ドーム・コーポレイション パピローマウイルスワクチン組成物
DK2925297T3 (da) * 2012-11-02 2017-10-02 Cytuvax Sammensætning omfattende cytokinmakroaggregater
JP7478144B2 (ja) * 2018-10-12 2024-05-02 セラム インスティチュート オブ インディア プライベイト リミテッド 低減用量の不活化ポリオウイルスを含む混合ワクチン組成物およびそれを調製するための方法
WO2020102728A1 (en) 2018-11-16 2020-05-22 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
US20230057939A1 (en) 2020-01-13 2023-02-23 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and a bispecific antibody
US20230210952A1 (en) 2020-02-05 2023-07-06 Washington University Method of treating a solid tumor with a combination of an il-7 protein and car-bearing immune cells
EP4232070A1 (en) 2020-10-26 2023-08-30 NeoImmuneTech, Inc. Methods of inducing stem cell mobilization
EP4236989A1 (en) 2020-11-02 2023-09-06 NeoImmuneTech, Inc. Use of interleukin-7 for the treatment of coronavirus
EP4240408A1 (en) 2020-11-05 2023-09-13 Neoimmunetech, Inc. Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine
AU2022283271A1 (en) 2021-05-24 2023-12-07 Provention Bio, Inc. Methods for treating type 1 diabetes
US20250099542A1 (en) 2021-12-30 2025-03-27 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and vegf antagonist
JP2026504619A (ja) 2022-11-07 2026-02-06 ネオイミューンテック， インコーポレイテッド 非メチル化ｍｇｍｔプロモーターを含む腫瘍を治療する方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
DE3818054C2 (de) * 1988-05-27 1994-02-17 Biotest Pharma Gmbh Verwendung einer Kombination aus einem Antigen bzw. einer Vakzine und humanem Interleukin zur Behandlung der Non-Responsiveness gegenüber immunologischen Defektzuständen
JPH0236129A (ja) * 1988-07-22 1990-02-06 Ajinomoto Co Inc ワクチン効果増強剤

Also Published As

Publication number Publication date
FI920132A0 (fi) 1992-01-13
EP0482076B1 (en) 1995-04-26
WO1991001143A1 (en) 1991-02-07
NO920161D0 (no) 1992-01-13
ATE121629T1 (de) 1995-05-15
DK0482076T3 (da) 1995-07-17
FI104233B (fi) 1999-12-15
JP3485184B2 (ja) 2004-01-13
CA2063587C (en) 2005-08-30
KR0177179B1 (ko) 1999-03-20
DE69018990T2 (de) 1995-12-14
ES2075900T3 (es) 1995-10-16
AU6050090A (en) 1991-02-22
FI104233B1 (fi) 1999-12-15
EP0482076A1 (en) 1992-04-29
AU648509B2 (en) 1994-04-28
DE69018990D1 (de) 1995-06-01
JP2004002463A (ja) 2004-01-08
JPH04506663A (ja) 1992-11-19
KR920703103A (ko) 1992-12-17
NO920161L (no) 1992-03-05
CA2063587A1 (en) 1991-01-15

Similar Documents

Publication Publication Date Title
NO301577B1 (no) Fremgangsmåte for fremstilling av en stabil vaksineblanding og fremgangsmåte for stabilisering av interleukin i en vaksineblanding
US7169391B2 (en) Vaccines
Nunberg et al. Interleukin 2 acts as an adjuvant to increase the potency of inactivated rabies virus vaccine.
US7374751B1 (en) QS-21 and IL-12 as an adjuvant combination
AU2001270031A1 (en) QS-21 and IL-12 as an adjuvant combination
IE914436A1 (en) Use of IL-4 to enhance immune response to immunogens in vaccines
JP2007511585A (ja) アルキルホスファチジルコリン配合ワクチン組成物
NZ250555A (en) Vaccine with enhanced immunogenicity by inclusion of a cytokine
AU2002225972B2 (en) Adjuvant combination formulations
WO1999040937A2 (en) Vaccines comprising interleukin-12 and respiratory syncytial viral antigens
EP1490100B1 (en) Combined dna/protein vaccine compositions
MXPA00007881A (en) Vaccines comprising interleukin-12 and respiratory syncytial viral antigens